Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics Group, Inc. (NASDAQ: TMDX) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the call by dialing (866) 807-9684 domestically or (412) 317-5415 internationally. TransMedics specializes in portable extracorporeal warm perfusion and organ assessment technology, aimed at improving organ transplantation outcomes for patients suffering from end-stage heart, lung, and liver diseases.
TransMedics Group, Inc. (NASDAQ: TMDX) has appointed Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. With 20 years of experience in global supply chain and commercial operations, including roles at Stryker Corporation, Corcoran will enhance TransMedics' operational efficiency to meet rising demand for OCS products. CEO Waleed Hassanein expressed confidence in Corcoran's ability to drive growth and optimize operations. TransMedics focuses on transforming organ transplant therapy through innovative technology, with headquarters in Andover, Massachusetts.
TransMedics Group, Inc. (Nasdaq: TMDX) announced its management team's presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 5:15 p.m. PST. The event will focus on TransMedics' innovative organ transplant therapies for patients with end-stage organ failures. A live and archived webcast will be available on their website. Established in Andover, Massachusetts, TransMedics leads in portable extracorporeal warm perfusion, aiming to enhance donor organ preservation and viability.
On November 2, 2022, TransMedics Group, Inc. (NASDAQ: TMDX) announced the granting of non-qualified stock options for 138,400 shares to six new employees as an inducement for their employment. This was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $46.36, reflecting the stock's closing price on the grant date. Vesting will occur at 25% after one year, with the remainder vesting monthly over three years, tied to continued employment.
TransMedics reported a net revenue of $25.7 million for Q3 2022, marking a 378% increase compared to Q3 2021. Revenue comprises $24.3 million in sales and a $1.4 million favorable adjustment. The company raised its 2022 revenue guidance to between $80 million and $85 million, reflecting 164% to 181% growth year-over-year. Gross margin improved to 71%, while operating expenses rose to $23.7 million. Despite a net loss of $7.4 million, cash reserves stand at $204.5 million.
TransMedics Group, Inc. (TMDX) will release its third-quarter 2022 financial results on November 3, 2022, after market close. A conference call is set for 4:30 p.m. ET to discuss the results, accessible via phone or through a live webcast on their website. TransMedics specializes in organ transplant technology, focusing on improving organ quality and viability for patients with end-stage heart, lung, and liver failure.
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. The event is scheduled for September 12, 2022, at 11:40 a.m. ET at the Sheraton New York. The management team will engage in a fireside chat, which will be accessible via a live and archived webcast on the company's investors' webpage.
TransMedics focuses on enhancing organ quality and viability assessments to improve transplant outcomes for patients with end-stage organ failure.
TransMedics Group announced an upsize and pricing of a public offering of 3,250,000 shares of common stock at $40.00 each, expected to raise $130 million in gross proceeds. The offering is set to close on August 9, 2022, pending customary conditions. An option exists for underwriters to purchase an additional 487,500 shares. The offering is registered under an automatic shelf registration statement filed with the SEC on August 3, 2022. This move aims to enhance the company's capacity in organ transplant therapy technologies.
TransMedics Group, Inc. (Nasdaq: TMDX) announced a proposed public offering of $100 million of its common stock, all to be offered by the company. A 30-day option for underwriters to purchase an additional 15% of the shares sold is expected. J.P. Morgan, Morgan Stanley, and Cowen are the lead managers of this offering, filed under a shelf registration statement with the SEC on August 3, 2022. Investors are urged to review the prospectus for detailed information. The announcement highlights TransMedics' commitment to organ transplant technology.
TransMedics Group reported a remarkable 151% increase in net revenue for Q2 2022, reaching $20.5 million compared to $8.2 million in Q2 2021. This growth is attributed to the use of the National OCS Program, which contributed 84% of total US revenue. The company has raised its 2022 revenue guidance to $67 million to $75 million, indicating an expected growth of 121% to 148% year-over-year. Additionally, TransMedics secured a $60 million non-dilutive debt financing to enhance financial flexibility.